STOCK TITAN

Brooklyn ImmunoTherapeutics Appoints Roger Sidhu, M.D. as Chief Medical Officer

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
management
Rhea-AI Summary

Brooklyn ImmunoTherapeutics (NYSE American: BTX) has appointed Dr. Roger Sidhu as Chief Medical Officer, effective September 20, 2021. Dr. Sidhu brings extensive R&D experience, including in late-stage clinical development for various cancers. His leadership is expected to guide the company through a critical phase, enhancing its mRNA-based gene editing and cellular reprogramming initiatives. Brooklyn's primary program, IRX-2, is in Phase 2B for head and neck cancer, following promising results in earlier trials. The company also focuses on developing therapies for blood disorders and genetic diseases.

Positive
  • Appointment of Dr. Roger Sidhu as Chief Medical Officer, bringing extensive experience in cancer treatment.
  • Dr. Sidhu's leadership expected to guide the company at a crucial stage of development.
  • IRX-2 shows potential with demonstrated overall survival benefit in Phase 2A trials for head and neck cancer.
Negative
  • None.

NEW YORK, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced the appointment of Roger Sidhu, M.D. as its Chief Medical Officer, effective September 20, 2021.

“Roger’s extensive R&D experience, including many years in late-stage clinical development involving a wide array of treatment modalities for hematologic malignancies and solid tumors, brings him to Brooklyn at an inflection point where his insight and understanding will help guide us to the next stage of our company’s development,” commented Howard J. Federoff, M.D., Ph.D., Brooklyn’s CEO and President. “We welcome Roger and look forward to collaborating with him in working to transform the way our targeted diseases are treated.”

“Brooklyn ImmunoTherapeutics’ cutting-edge mRNA-based gene editing and cellular reprogramming platform positions the company at the forefront of an emerging personalized medicine revolution, and I look forward to having a guiding hand in driving the company forward as a leader in the field,” added Dr. Sidhu.

Prior to joining Brooklyn, Dr. Sidhu served as Vice President, Clinical Development at Kite Pharma, a subsidiary of Gilead Sciences. Previously, he held key positions at Roivant Sciences, where he was Chief Medical Officer and Executive Vice President and Head of Research and Development, Cell Design Labs, where he served as Chief Medical Officer, and Amgen, where he served as Global Product General Manager, Translational Sciences. Dr. Sidhu is a Fellow of the Royal College of Physicians and Surgeons of Canada in both internal medicine and medical oncology. He earned a Bachelor of Science (Biochemistry) from University of Alberta, and his M.D. from Queen’s University, Kingston, Ontario, where he also did his residency.

About Brooklyn ImmunoTherapeutics
Brooklyn is focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases.

Brooklyn’s most advanced program is IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B. In a Phase 2A clinical trial in head and neck cancer, IRX-2 demonstrated an overall survival benefit. Additional studies are either underway or planned in other solid tumor cancer indications.

Brooklyn has multiple next-generation cell and gene-editing therapies in preclinical development for various indications including acute respiratory distress syndrome, solid tumor indications, as well as in vivo gene-editing therapies for rare genetic diseases. For more information about Brooklyn and its clinical programs, please visit www.BrooklynITx.com.

Investor Relations Contact:
CORE IR
516-222-2560
investors@brooklynitx.com

Media Contact:
Jules Abraham
CORE IR
917-885-7378
julesa@coreir.com


FAQ

Who is the new Chief Medical Officer of Brooklyn ImmunoTherapeutics?

Dr. Roger Sidhu has been appointed as the Chief Medical Officer of Brooklyn ImmunoTherapeutics.

What experience does Dr. Sidhu bring to Brooklyn ImmunoTherapeutics?

Dr. Sidhu has extensive R&D experience in late-stage clinical development, particularly for hematologic malignancies and solid tumors.

What is the primary focus of Brooklyn ImmunoTherapeutics?

Brooklyn focuses on cytokine, gene editing, and cell therapy for treating cancer, blood disorders, and monogenic diseases.

What is the status of Brooklyn’s IRX-2 program?

IRX-2 is currently in Phase 2B clinical trials for head and neck cancer, building on promising Phase 2A results.

BTX

NASDAQ:BTX

BTX Rankings

BTX Latest News

BTX Stock Data

12.04M
34.05M
42.2%
26.23%
1.74%
Biotechnology
Healthcare
Link
United States
San Diego